Mirtazapin Sandoz (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Sandoz, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapin Sandoz, a NaSSA antidepressant, is used within the mood‑disorder therapeutic area. - Major depressive disorder: alleviates depressive symptoms and improves functional outcomes in adults. - Depressive episodes with prominent anxiety: helps reduce anxiety‑related symptoms while treating depression. - Depression associated with insomnia: improves sleep quality and mood concurrently.

Mirtazapin Sandoz may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness or light‑headedness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Suicidal thoughts or worsening depression - Hepatotoxicity (liver injury) - Serotonin syndrome, especially with other serotonergic drugs - Severe allergic reactions (e.g., angioedema)

Before initiating therapy, clinicians should consider several safety measures. - Hepatic function: assess liver enzymes in patients with existing liver disease. - Suicidality: monitor for emergence or worsening of suicidal thoughts, especially early in treatment. - Cardiovascular status: use caution in patients with hypotension or arrhythmias. - Discontinuation: avoid abrupt cessation to reduce risk of withdrawal symptoms. - Drug interactions: review concomitant medications for potential additive CNS depression. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapin Sandoz can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis or serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - Strong CYP3A4 inhibitors (ketoconazole, itraconazole): may raise mirtazapine plasma levels. - CNS depressants (benzodiazepines, alcohol): additive sedation and respiratory depression. - H1‑antagonists with sedative properties: excessive drowsiness.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may reduce therapeutic effect. - Antihypertensive drugs: potential additive hypotensive effect. - Anticholinergic medications: may worsen dry mouth and constipation. - NSAIDs or anticoagulants: heightened risk of gastrointestinal bleeding. - Lithium: possible increase in neurotoxicity.